

CORRECTION

Correction: Brivanib Attenuates Hepatic Fibrosis *In Vivo* and Stellate Cell Activation *In Vitro* by Inhibition of FGF, VEGF and PDGF Signaling

Ikuro Nakamura, Kais Zakharia, Bubu A. Banini, Dalia S. Mikhail, Tae Hyo Kim, Ju Dong Yang, Catherine D. Moser, Hassan M. Shaleh, Sarah R. Thornburgh, Ian Walters, Lewis R. Roberts

The following information is missing from the Funding section: This research was supported by a National Institutes of Health (NIH) grant, 3R01CA165076-03S2, Research Supplement to Promote Diversity in Health-Related Research, to Hassan M. Shaleh.

Reference

1. Nakamura I, Zakharia K, Banini BA, Mikhail DS, Kim TH, Yang JD, et al. (2014) Brivanib Attenuates Hepatic Fibrosis *In Vivo* and Stellate Cell Activation *In Vitro* by Inhibition of FGF, VEGF and PDGF Signaling. PLoS ONE 9(4): e92273. doi:[10.1371/journal.pone.0092273](https://doi.org/10.1371/journal.pone.0092273) PMID: [24710173](https://pubmed.ncbi.nlm.nih.gov/24710173/)



OPEN ACCESS

Citation: Nakamura I, Zakharia K, Banini BA, Mikhail DS, Kim TH, Yang JD, et al. (2015) Correction: Brivanib Attenuates Hepatic Fibrosis *In Vivo* and Stellate Cell Activation *In Vitro* by Inhibition of FGF, VEGF and PDGF Signaling. PLoS ONE 10(11): e0142355. doi:[10.1371/journal.pone.0142355](https://doi.org/10.1371/journal.pone.0142355)

Published: November 3, 2015

Copyright: © 2015 Nakamura et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.